{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:23:33Z","timestamp":1787509413849,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0012"],"award-info":[{"award-number":["P1-0012"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P4-0127"],"award-info":[{"award-number":["P4-0127"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P4-0053"],"award-info":[{"award-number":["P4-0053"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.apsb.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:43:45Z","timestamp":1751917425000},"page":"4807-4828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pleiotropic prodrugs for both symptomatic and disease-modifying treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-6579","authenticated-orcid":false,"given":"An\u017ee","family":"Meden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ne\u017ea","family":"\u017dnidar\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9917-1384","authenticated-orcid":false,"given":"Damijan","family":"Knez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-1024","authenticated-orcid":false,"given":"Anja","family":"Pi\u0161lar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-9231","authenticated-orcid":false,"given":"Andrej","family":"Perdih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-7841","authenticated-orcid":false,"given":"Simona Kranjc","family":"Brezar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ne\u017ea","family":"Grgurevi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stane","family":"Pajk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-3083","authenticated-orcid":false,"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.07.005_bib1","series-title":"Global status report on the public health response to dementia","year":"2021"},{"key":"10.1016\/j.apsb.2025.07.005_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2025.07.005_bib3","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"10.1016\/j.apsb.2025.07.005_bib4","first-page":"1","article-title":"History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2025.07.005_bib5","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1007\/s11064-021-03415-w","article-title":"Multifaceted Alzheimer\u2019s disease: building a roadmap for advancement of novel therapies","volume":"46","author":"Kaur","year":"2021","journal-title":"Neurochem Res"},{"key":"10.1016\/j.apsb.2025.07.005_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.07.005_bib7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/acschemneuro.8b00391","article-title":"Reconsideration of anticholinesterase therapeutic strategies against Alzheimer\u2019s disease","volume":"10","author":"Wang","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.apsb.2025.07.005_bib8","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2025.07.005_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","article-title":"The history of the cholinergic hypothesis","volume":"221","author":"Contestabile","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2025.07.005_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.11.011","article-title":"Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses","volume":"148","author":"Lockridge","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.07.005_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/med.21745","article-title":"Structure and therapeutic uses of butyrylcholinesterase: application in detoxification, Alzheimer\u2019s disease, and fat metabolism","volume":"41","author":"Xing","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2025.07.005_bib12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.62.2.220","article-title":"Re-engineering butyrylcholinesterase as a cocaine hydrolase","volume":"62","author":"Sun","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib13","article-title":"Blocking drug activation as a therapeutic strategy to attenuate acute toxicity and physiological effects of heroin","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer \u03b2-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105167","article-title":"Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing","volume":"149","author":"Orlando","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.apsb.2025.07.005_bib16","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.3390\/ijms23116143","article-title":"Noradrenaline in Alzheimer\u2019s disease: a new potential therapeutic target","volume":"23","author":"Guti\u00e9rrez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brainresrev.2004.02.002","article-title":"Noradrenergic mechanisms in neurodegenerative diseases: a theory","volume":"45","author":"Marien","year":"2004","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.apsb.2025.07.005_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnins.2015.00220","article-title":"Noradrenergic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Gannon","year":"2015","journal-title":"Front Neurosci"},{"key":"10.1016\/j.apsb.2025.07.005_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2018.01.001","article-title":"Complex noradrenergic dysfunction in Alzheimer\u2019s disease: low norepinephrine input is not always to blame","volume":"1702","author":"Gannon","year":"2019","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2025.07.005_bib20","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1073\/pnas.0909586107","article-title":"Locus ceruleus controls Alzheimer\u2019s disease pathology by modulating microglial functions through norepinephrine","volume":"107","author":"Heneka","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4103\/1673-5374.193241","article-title":"Beta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer\u2019s disease mice","volume":"11","author":"Chai","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.apsb.2025.07.005_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2019.08.007","article-title":"The role of Locus coeruleus in neuroinflammation occurring in Alzheimer\u2019s disease","volume":"153","author":"Giorgi","year":"2019","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.apsb.2025.07.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113179","article-title":"The Locus coeruleus\u2014noradrenaline system: looking into Alzheimer\u2019s therapeutics with rose coloured glasses","volume":"151","author":"Behl","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.07.005_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.397","article-title":"Alzheimer\u2019s disease: an evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies","volume":"11","author":"Slater","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.apsb.2025.07.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.10.088","article-title":"Structural basis of the diversity of adrenergic receptors","volume":"29","author":"Qu","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2025.07.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.10.112","article-title":"Molecular mechanism for ligand recognition and subtype selectivity of \u03b12c adrenergic receptor","volume":"29","author":"Chen","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2025.07.005_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj5347","article-title":"Structural insights into ligand recognition, activation, and signaling of the \u03b12A adrenergic receptor","volume":"8","author":"Xu","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.07.005_bib28","series-title":"The alpha-2 Adrenergic Receptors","first-page":"115","article-title":"Structure\u2013activity relationships for alpha-2 adrenergic receptor agonists and antagonists","author":"Ruffolo","year":"1988"},{"key":"10.1016\/j.apsb.2025.07.005_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6931","article-title":"\u03b2-Amyloid redirects norepinephrine signaling to activate the pathogenic GSK3\u03b2\/tau cascade","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.07.005_bib30","doi-asserted-by":"crossref","first-page":"17296","DOI":"10.1073\/pnas.1409513111","article-title":"\u03b12A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction","volume":"111","author":"Chen","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","article-title":"Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade","volume":"119","author":"Savelieff","year":"2019","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2025.07.005_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","article-title":"A Perspective on multi-target drugs for Alzheimer\u2019s disease","volume":"41","author":"Benek","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17460441.2019.1623201","article-title":"Developments with multi-target drugs for Alzheimer\u2019s disease: an overview of the current discovery approaches","volume":"14","author":"Gonz\u00e1lez","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.apsb.2025.07.005_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nchembio.579","article-title":"Click-generated triazole ureas as ultrapotent in vivo\u2013active serine hydrolase inhibitors","volume":"7","author":"Adibekian","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2025.07.005_bib36","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bmc.2019.03.020","article-title":"N-Acyl pyrazoles: effective and tunable inhibitors of serine hydrolases","volume":"27","author":"Otrubova","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib37","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/molecules24152786","article-title":"Inhibiting acetylcholinesterase to activate pleiotropic prodrugs with therapeutic interest in Alzheimer\u2019s disease","volume":"24","author":"Toublet","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.07.005_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113059","article-title":"Pleiotropic prodrugs: design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer\u2019s disease","volume":"210","author":"Toublet","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib39","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1351\/pac199870051129","article-title":"Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)","volume":"70","author":"Wermuth","year":"1998","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.1990.tb03748.x","article-title":"Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist-a randomized, double-blind cross-over study in healthy male volunteers","volume":"30","author":"Karhuvaara","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1527-3458.2005.tb00047.x","article-title":"Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective \u03b12-adrenoceptor antagonist","volume":"11","author":"Pertovaara","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.apsb.2025.07.005_bib42","first-page":"916","article-title":"Effects of early atipamezole reversal of medetomidine\u2013ketamine anesthesia in mice","volume":"50","author":"Baker","year":"2011","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejps.2019.01.010","article-title":"Atipamezole is a promising non-discriminative inhibitor against pan-CYP450 including diclofenac 4\u2032-hydroxylation: a comparison with ABT for drug ADME optimization and mechanism study","volume":"130","author":"Li","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1124\/dmd.119.089151","article-title":"Assessment and confirmation of species difference in nonlinear pharmacokinetics of atipamezole with physiologically based pharmacokinetic modeling","volume":"48","author":"Li","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2025.07.005_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113844","article-title":"2-Pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the amyloid \u03b2-induced Alzheimer-like mice model: bring the \u03b12 adrenergic receptor back into play","volume":"156","author":"Infantino","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.07.005_bib46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1124\/jpet.301.1.187","article-title":"Effects of acute and subchronic administration of dexefaroxan, an \u03b12-adrenoceptor antagonist, on memory performance in young adult and aged rodents","volume":"301","author":"Chopin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2025.07.005_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02247440","article-title":"\u03b12-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat","volume":"124","author":"Camacho","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.apsb.2025.07.005_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(98)00077-6","article-title":"Facilitation of cognitive functions by a specific \u03b12-adrenoceptor antagonist, atipamezole","volume":"347","author":"Haapalinna","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(99)00819-5","article-title":"The effects of a specific \u03b12-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats","volume":"387","author":"Haapalinna","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-2999(88)90391-3","article-title":"Behavioural and neurochemical effects of atipamezole, a novel \u03b12-adreneceptor antagonist","volume":"157","author":"Scheinin","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-2999(91)90817-A","article-title":"Effects of atipamezole, a novel \u03b12-adrenoceptor antagonist, in open-field, plus-maze, two compartment exploratory, and forced swimming tests in the rat","volume":"205","author":"Kauppila","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib52","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.bmc.2016.05.043","article-title":"A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin","volume":"24","author":"Vucicevic","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115048","article-title":"Pseudo-irreversible butyrylcholinesterase inhibitors: structure\u2013activity relationships, computational and crystallographic study of the N-dialkyl O-arylcarbamate warhead","volume":"247","author":"Meden","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib54","series-title":"Heteroaromatic Nitrogen compounds: the Azoles","author":"Schofield","year":"2011"},{"key":"10.1016\/j.apsb.2025.07.005_bib55","series-title":"4-Dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobe nzofuran-2-ylimidazoles, useful to block alpha 2-adrenergic receptors","author":"Karjalainen","year":"1987"},{"key":"10.1016\/j.apsb.2025.07.005_bib56","series-title":"Indenyl imidazoles","author":"Karjalainen","year":"1991"},{"key":"10.1016\/j.apsb.2025.07.005_bib57","series-title":"Treatment of age related memory impairment and other cognitive disorders","author":"Lammintausta","year":"1991"},{"key":"10.1016\/j.apsb.2025.07.005_bib58","series-title":"Imidazole derivatives having affinity for alpha2 receptors","author":"Karjalainen","year":"2001"},{"key":"10.1016\/j.apsb.2025.07.005_bib59","series-title":"Imidazole derivatives","author":"Huhtala","year":"2002"},{"key":"10.1016\/j.apsb.2025.07.005_bib60","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/ejoc.200500143","article-title":"Preparation of Conformationally constrained \u03b12 antagonists:the bicyclo[3.1.0]hexane approach","volume":"2005","author":"Bonnaud","year":"2005","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib61","series-title":"Novel imidazolic compounds, method for preparing same and use thereif as medicines","author":"Vacher","year":"2006"},{"key":"10.1016\/j.apsb.2025.07.005_bib62","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1021\/jm1006269","article-title":"Rigid analogues of the \u03b12-adrenergic blocker atipamezole: small changes, big consequences","volume":"53","author":"Vacher","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib63","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1124\/mol.107.033928","article-title":"The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates","volume":"71","author":"Groner","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2025.07.005_bib64","series-title":"Comprehensive Toxicology","first-page":"277","article-title":"10.14 - Esterases","author":"Lockridge","year":"2018"},{"key":"10.1016\/j.apsb.2025.07.005_bib65","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00695604","article-title":"Relationship between specific gravity, water content, and serum protein extravasation in various types of vasogenic brain edema","volume":"64","author":"Bothe","year":"1984","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.apsb.2025.07.005_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1125618","article-title":"Potential revival of cholinesterase inhibitors as drugs in veterinary medicine","volume":"10","author":"\u017dnidar\u0161i\u010d","year":"2023","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.apsb.2025.07.005_bib67","article-title":"Intracerebroventricular injection of amyloid-\u03b2 peptides in normal mice to acutely induce alzheimer-like cognitive deficits","volume":"109","author":"Kim","year":"2016","journal-title":"JoVE"},{"key":"10.1016\/j.apsb.2025.07.005_bib68","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2025.07.005_bib69","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/nprot.2013.155","article-title":"Object recognition test in mice","volume":"8","author":"Leger","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2025.07.005_bib70","series-title":"Pre-clinical models: techniques and protocols","first-page":"105","article-title":"The Y-maze for assessment of spatial working and reference memory in mice","author":"Kraeuter","year":"2019"},{"key":"10.1016\/j.apsb.2025.07.005_bib71","series-title":"Piperidino derivatives which promote growth hormone release","author":"Taniguchi","year":"1998"},{"key":"10.1016\/j.apsb.2025.07.005_bib72","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/acscatal.2c02214","article-title":"Copper-catalyzed enantioselective oxysulfenylation of alkenols: synthesis of arylthiomethyl-substituted cyclic ethers","volume":"12","author":"Burde","year":"2022","journal-title":"ACS Catal"},{"key":"10.1016\/j.apsb.2025.07.005_bib73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jlcr.532","article-title":"Synthesis of [11C]atipamezole, a potential PET ligand for the \u03b12-adrenergic receptor in the brain","volume":"45","author":"Roeda","year":"2002","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.apsb.2025.07.005_bib74","doi-asserted-by":"crossref","first-page":"9172","DOI":"10.1039\/C9CC03644J","article-title":"Intramolecular palladium(II)\/(IV) catalysed C(sp3)\u2013H arylation of tertiary aldehydes using a transient imine directing group","volume":"55","author":"John Campbell","year":"2019","journal-title":"Chem Commun"},{"key":"10.1016\/j.apsb.2025.07.005_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3987\/COM-93-S(B)8","article-title":"A two-step synthesis of imidazoles from aldehydes via 4-tosyloxazolines","volume":"39","author":"B\u00fcchi","year":"1994","journal-title":"Heterocycles"},{"key":"10.1016\/j.apsb.2025.07.005_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-1995-3884","article-title":"A concise synthesis of atipamezole","volume":"1995","author":"Wong","year":"1995","journal-title":"Synthesis"},{"key":"10.1016\/j.apsb.2025.07.005_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/00304948.2019.1621085","article-title":"Reinvestigation of atipamezole synthesis and preparation of new analogs","volume":"51","author":"Karrabi","year":"2019","journal-title":"Org Prep Proced Int"},{"key":"10.1016\/j.apsb.2025.07.005_bib78","series-title":"Atipamezole hydrochloride crystallization method","author":"Parhi","year":"2008"},{"key":"10.1016\/j.apsb.2025.07.005_bib79","series-title":"Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-Yl)-1H-imidazole and salts thereof","author":"Lusis","year":"2011"},{"key":"10.1016\/j.apsb.2025.07.005_bib80","series-title":"Preparation method of atipamezole","author":"Yingbo","year":"2020"},{"key":"10.1016\/j.apsb.2025.07.005_bib81","series-title":"Preparation method of atipamezole","author":"Jin","year":"2021"},{"key":"10.1016\/j.apsb.2025.07.005_bib82","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1248\/cpb.30.3849","article-title":"New Methods and reagents in organic synthesis. 32. Lithium trimethylsilyldiazomethane: a new synthon for the preparation of 1,2,3-triazoles","volume":"30","author":"Aoyama","year":"1982","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.apsb.2025.07.005_bib83","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1021\/jo01337a031","article-title":"New synthesis of 1,2,4-triazoles and 1,2,4-oxadiazoles","volume":"44","author":"Lin","year":"1979","journal-title":"J Org Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib84","series-title":"Proceedings of the 2006 ACM\/IEEE conference on Supercomputing","first-page":"84","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006"},{"key":"10.1016\/j.apsb.2025.07.005_bib85","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/pro.4219","article-title":"Spatial arrangement of proteins in planar and curved membranes by PPM 3.0","volume":"31","author":"Lomize","year":"2022","journal-title":"Protein Sci Publ Protein Soc"},{"key":"10.1016\/j.apsb.2025.07.005_bib86","doi-asserted-by":"crossref","first-page":"D370","DOI":"10.1093\/nar\/gkr703","article-title":"OPM database and PPM web server: resources for positioning of proteins in membranes","volume":"40","author":"Lomize","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2025.07.005_bib87","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.apsb.2025.07.005_bib88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins Struct Funct Bioinforma"},{"key":"10.1016\/j.apsb.2025.07.005_bib89","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: a software program for pKa prediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.apsb.2025.07.005_bib90","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.apsb.2025.07.005_bib91","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.07.005_bib92","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated modeling program, applied chemical theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib93","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.apsb.2025.07.005_bib94","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2013ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.07.005_bib95","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2025.07.005_bib96","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J Chem Phys"},{"key":"10.1016\/j.apsb.2025.07.005_bib97","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41467-021-27911-3","article-title":"Crystal structure of the \u03b11B-adrenergic receptor reveals molecular determinants of selective ligand recognition","volume":"13","author":"Deluigi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.07.005_bib98","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1021\/jacs.1c13492","article-title":"Photoswitchable pseudoirreversible butyrylcholinesterase inhibitors allow optical control of inhibition in vitro and enable restoration of cognition in an Alzheimer\u2019s disease mouse model upon irradiation","volume":"144","author":"Scheiner","year":"2022","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.07.005_bib99","series-title":"OECD Test No. 423: Acute oral toxicity\u2014acute toxic class method","year":"2002"},{"key":"10.1016\/j.apsb.2025.07.005_bib100","series-title":"Veterinary pharmacology and therapeutics","author":"Papich","year":"2017"},{"key":"10.1016\/j.apsb.2025.07.005_bib101","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1046\/j.1471-4159.2000.751320.x","article-title":"Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse","volume":"75","author":"Li","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2025.07.005_bib102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/toxres\/tfaa057","article-title":"Inhibition of rat brain and human red cell acetylcholinesterase by thiocarbamate herbicides","volume":"9","author":"Lock","year":"2020","journal-title":"Toxicol Res"},{"key":"10.1016\/j.apsb.2025.07.005_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114806","article-title":"Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer\u2019s disease","volume":"244","author":"Wang","year":"2022","journal-title":"Eur J Med Chem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525004605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525004605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:21:06Z","timestamp":1762604466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525004605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2211383525004605"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.07.005","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleiotropic prodrugs for both symptomatic and disease-modifying treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}